Sunmax Biotechnology Valuation
| 4728 Stock | TWD 275.50 2.50 0.90% |
At this time, the company appears to be fairly valued. Sunmax Biotechnology has a current Real Value of NT$272.0 per share. The regular price of the company is NT$275.5. Our model measures the value of Sunmax Biotechnology from inspecting the company fundamentals such as Shares Owned By Institutions of 9.24 %, return on equity of 0.48, and Operating Margin of 0.56 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Sunmax Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of Sunmax Biotechnology is based on 3 months time horizon. Increasing Sunmax Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sunmax stock is determined by what a typical buyer is willing to pay for full or partial control of Sunmax Biotechnology Co. Since Sunmax Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sunmax Stock. However, Sunmax Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 275.5 | Real 272.0 | Hype 275.5 | Naive 273.66 |
The intrinsic value of Sunmax Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sunmax Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sunmax Biotechnology Co helps investors to forecast how Sunmax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sunmax Biotechnology more accurately as focusing exclusively on Sunmax Biotechnology's fundamentals will not take into account other important factors: Sunmax Biotechnology Total Value Analysis
Sunmax Biotechnology Co is presently anticipated to have takeover price of 8.1 B with market capitalization of 7.19 B, debt of 0, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sunmax Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.1 B | 7.19 B | 0 |
Sunmax Biotechnology Investor Information
About 41.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 9.24. Sunmax Biotechnology last dividend was issued on the 13th of July 2022. Based on the key measurements obtained from Sunmax Biotechnology's financial statements, Sunmax Biotechnology Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Sunmax Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sunmax Biotechnology has an asset utilization ratio of 69.79 percent. This indicates that the Company is making NT$0.7 for each dollar of assets. An increasing asset utilization means that Sunmax Biotechnology Co is more efficient with each dollar of assets it utilizes for everyday operations.Sunmax Biotechnology Ownership Allocation
Sunmax Biotechnology shows a total of 54.46 Million outstanding shares. Sunmax Biotechnology maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sunmax Biotechnology Profitability Analysis
The company reported the revenue of 1.04 B. Net Income was 245.64 M with profit before overhead, payroll, taxes, and interest of 894.45 M.About Sunmax Biotechnology Valuation
Our relative valuation model uses a comparative analysis of Sunmax Biotechnology. We calculate exposure to Sunmax Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sunmax Biotechnology's related companies.8 Steps to conduct Sunmax Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sunmax Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sunmax Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sunmax Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sunmax Biotechnology's revenue streams: Identify Sunmax Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sunmax Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sunmax Biotechnology's growth potential: Evaluate Sunmax Biotechnology's management, business model, and growth potential.
- Determine Sunmax Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sunmax Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Sunmax Stock Analysis
When running Sunmax Biotechnology's price analysis, check to measure Sunmax Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunmax Biotechnology is operating at the current time. Most of Sunmax Biotechnology's value examination focuses on studying past and present price action to predict the probability of Sunmax Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunmax Biotechnology's price. Additionally, you may evaluate how the addition of Sunmax Biotechnology to your portfolios can decrease your overall portfolio volatility.